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http://dx.doi.org/10.1016/j.immuni.2015.11.023Importantly, we all agree that most
adult mouse tissue-resident macro-
phages (trMs) have fetal origins. Our inter-
pretations about the nature of those fetal
precursors, however, differ from those of
other investigators. Gomez Perdiguero
et al. hypothesize that all adult trMs are
derived from yolk sac erythro-myeloid
precursors (EMPs) (Gomez Perdiguero
et al., 2015), whereas we propose that
only brain microglia (and part of Langer-
hans cells [LCs]) are derived from EMPs
and that all other adult trMs are products
of fetal hematopoietic stem cells (HSCs)
(Sheng et al., 2015).
We were persuaded to adopt the
‘‘HSC wave hypothesis’’ because in
our fate-mapping system (based on
KITMercreMer/R26YFPmice), a single injection
of tamoxifen at embryonic day 7.5 (E7.5)
led to robust YFP labeling of adult micro-
glia (and part of LCs) but not of other
peripheral hematopoietic cells. However,
injection of tamoxifen 1 day later (E8.5)
labeled all adult peripheral hematopoietic
cells (lymphocytes, neutrophils, and trMs)
and, importantly, didso to thesameextent,
suggesting a common source. Therefore,
we suggest that this source was fetal
HSCs, especially becauseHSCsappeared
at this time in mouse embryos, and the
distribution of differentiated cell types
reflected the typical output of HSCs.
We agree with Gomez Perdiguero
et al. (2015) that to refute the ‘‘EMP-
only’’ hypothesis, we should show thatwe can label embryonal EMPs without
consequent peripheral labeling of adult
trMs. We accept that microglia (and part
of LCs) are derived from yolk sac EMPs.
Reassuringly, a tamoxifen pulse on E7.5
in our system tagged robustly adult mi-
croglia, showing that we can label at least
microglial precursor EMPs without any
consequent contribution to other trMs. It
is possible, however, that at E7.5, other
subpopulations of EMPs (EMP2s) for
other trMs have not yet developed in the
yolk sac and hence cannot be tagged at
that stage because these precursors are
still KIT. We think this is unlikely: we
agree that at E10.5, putative EMP2s in
the yolk sac are in the KIT+ fraction.
Importantly, we could label that fraction
very efficiently (60%–70%) after an E7.5
tamoxifen pulse. However, Gomez Perdi-
guero et al. (2015) argue that because
all EMPs are SCA1, we missed them
because we gated on SCA1+ cells. In
our analysis (Figure 5A in Sheng et al.,
2015), perhaps artifactually, all KIT+ cells
were SCA1+, and hence we did not
exclude any cells from our analysis (gating
only on KIT+ cells gave the same results).
However, we cannot exclude the possibil-
ity that regardless of high labeling effi-
ciency, all putative EMP2s were found
only in the YFP unlabeled fraction in the
KIT+ E10.5 yolk sac cells, i.e., in this
case, labeled cells do not reflect the
whole Kit+ population assumption that
is implicit in all inductive systems. Inci-Immunity 43, Dedentally, if the YFP fraction contains
all EMP2s, our labeling efficiency for
EMP1s must be correspondingly higher
than 60%–70%, conditions that are
hardly ever met in inductive systems.
We did not functionally analyze the
developmental potential of cells in popu-
lations containing EMPs as Gomez Perdi-
guero et al. (Gomez Perdiguero et al.,
2015) did because we felt it unnecessary
for our study, and we do not challenge
their results—they are robust and reflect
the cellular composition of those early tis-
sues. Interestingly though, the study of
Hoeffel et al. (2015) recently showed that
a wave of fetal monocytes replaced the
early EMP-derived macrophages in all tis-
sues, and we would argue that this wave
was the product of fetal HSCs and not
EMPs as the authors speculate (Hoeffel
et al., 2015).
To definitely settle the details of the
origins, we need more specific genetic
tracers and clonal in vivo assays, which
will probably be developed in the future.
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